Company news
Correvio Pharma Corp news in 2017
Correvio Pharma Corp's news releases, calls and decks from 2017, newest first.
Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia
December 12, 2017
Cardiome Highlights Partner SteadyMed's Agreement With FDA On Pathway To Trevyent NDA Resubmission
December 11, 2017
Cardiome Announces Xydalba(TM) Treatment And Patient Experience Presentations At The 2017 National Opat Conference
December 11, 2017
Cardiome to Present at the 29th Annual Piper Jaffray Healthcare Conference
November 20, 2017
Cardiome Reports Third Quarter 2017 Financial Results
November 14, 2017
Cardiome To Hold Third Quarter 2017 Financial Results Conference Call On November 14
November 7, 2017
Cardiome Announces Expansion of Global Geographic Footprint for Brinavess®
November 2, 2017
Cardiome Announces Commercial Launch of Xydalba(TM) in Three New European Geographies
October 30, 2017
Cardiome Announces Agreement with Basilea for Distribution of Zevtera®/Mabelio® (Ceftobiprole) in Europe and Israel
September 12, 2017
Cardiome to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
September 5, 2017
New Data Presented at European Society of Cardiology Congress 2017 Highlights Clinical Benefit of BRINAVESS®
August 30, 2017
Cardiome Provides U.S. Regulatory Update For BRINAVESS
August 21, 2017
Cardiome Reports Second Quarter 2017 Financial Results
August 8, 2017
Cardiome To Hold Second Quarter 2017 Financial Results Conference Call On August 8
August 1, 2017
Cardiome Announces Health Canada Approval of AGGRASTAT® High Dose Bolus Regimen
July 17, 2017
Cardiome's Partner SteadyMed Submits U.S. New Drug Application for TREVYENT® for the Treatment of Pulmonary Arterial Hypertension
July 3, 2017
Cardiome Announces Licensing Agreement for XYDALBA(TM) (Dalbavancin Hydrochloride) to Support Planned Commercialization in Israel
June 21, 2017
Cardiome Announces Commercial Launch of BRINAVESS® (Vernakalant Hydrochloride) in Canada
June 12, 2017
Cardiome Reports Changes To Senior Management Team
May 16, 2017
Cardiome Reports First Quarter 2017 Financial Results
May 15, 2017
Cardiome Announces Amendment to Term Loan Agreement with CRG-Managed Funds
May 15, 2017
Cardiome To Hold First Quarter 2017 Financial Results Conference Call On May 15
May 8, 2017
Cardiome to Present at the Bloom Burton & Co. 6th Annual Healthcare Investor Conference
April 27, 2017
Cardiome's Partner SteadyMed Announces Successful Completion of Trevyent® Clinical Validation Study
April 6, 2017
Cardiome's Partner SteadyMed Receives Favourable Ruling in its USPTO Inter Partes Review
April 3, 2017
Cardiome Receives Notice of Compliance from Health Canada for its BRINAVESS NDS
March 14, 2017
Cardiome Reports Fourth Quarter and Full Year 2016 Financial Results
March 7, 2017
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in France
March 3, 2017
Cardiome To Hold Fourth Quarter And Full Year 2016 Financial Results Conference Call On March 7
February 27, 2017